ChartRow logo
NVO
$42.18+4.95%
as of close, Nov 4, 2026
☾ AH $42.18 +4.95%
PeersNVSPFEGILDAMGNBMYSNY
Share this page

NVO — Novo Nordisk A/S price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in NVO be worth today? →
NVO returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$42.18
YTD price return
-17.10%
YTD total return
-12.96%
Market cap
187.4B
Enterprise value
203.9B
Shares outstanding
4.4B
52W low
$35.12
52W high
$64.16
From 52W high
-34.26%
From 52W low
+20.10%
52W range
24%$35.12–$64.16
Beta
0.74

Volume

Rel volume
2.14×
30D volume
11.9M
30D $ vol
464M

Fundamentals

Sales (ttm)
46.6B
Sales/share
$10.50
EPS (ttm)
$3.48
FCF (ttm)
8.9B
FCF/share
$2.00
Book value/share
$6.87
Net margin
33.14%
ROE
50.62%
ROA
18.09%
Debt / equity
0.61×
Current ratio
0.80

Growth (CAGR, ttm) · 10Y

Sales
+10.85%+23.09%+19.16%n/a
Net income
+5.65%+25.36%+19.13%n/a
FCF
-16.80%-1.92%+4.76%n/a
Shares
+0.07%-0.42%-1.11%n/a

Per-share growth (CAGR, ttm) · 10Y

EPS
+6.00%+26.25%+20.34%n/a
Sales/share
+10.78%+23.60%+20.51%n/a
FCF/share
-16.86%-1.51%+5.94%n/a
Book value/share
+52.70%+37.05%+25.46%n/a
Dividend/share
+6.90%+26.31%+20.47%n/a
Price
-12.59%-24.52%-6.15%+9.28%
Total return
-8.22%-22.30%-4.02%+11.76%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
12.1×
P/OI (ttm)
9.7×
Fwd P/E
12.1×
P/S (ttm)
4.0×
P/B (mrq)
6.1×
P/FCF (ttm)
21.1×
EV/EBITDA (fy)
9.5×
EV/Sales (ttm)
4.4×
FCF yield (ttm)
4.75%
Dividend yield (ttm)Div yield (ttm)
4.40%
Buyback yield (realized, 1y)
-0.07%
Shareholder yield (realized, 1y)
1.98%
Buyback yield (cash, ttm)
0.11%
Shareholder yield (cash, ttm)
4.28%

Vs own 10Y history

P/E
5th
P/OI
5th
P/S
5th
P/B
5th
P/FCF
8th

Bar = where today’s multiple sits in NVO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+4.95%
5D
+10.16%
1M
+13.02%
3M
-4.74%
YTD
-17.10%
1Y
-12.58%
5Y
-27.18%
1D
+4.95%
5D
+10.16%
1M
+13.02%
3M
-3.53%
YTD
-12.96%
1Y
-8.22%
5Y
-18.55%

Fundamentals#

Revenue

5Y CAGR +19.2%5Y CAGR +19.2%
$46.6B FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y CAGR +18.4%5Y CAGR +18.4%
$19.3B FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y CAGR +20.3%5Y CAGR +20.3%
$3.48 FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y CAGR +4.8%5Y CAGR +4.8%
$8.9B FY25
FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $18B, capex −$9.1B

No quarters filed for this figure.

Shares (diluted)

5Y −5.0%5Y −5.0%
4.4B FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Dividend per share

5Y CAGR +20.5%5Y CAGR +20.5%
$1.77 FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full NVO financials →

About Novo Nordisk#

Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.

Bagsvaerd, Denmark·66,700 employees·Drug Manufacturers - General·novonordisk.com·As of Oct 28, 2026

Recent filings#

No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.

All filings and insider trades →

ETFs holding NVO#

13 of the 193 ETFs ChartRow carries live hold NVO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VIGIVanguard International Dividend Appreciation ETF2.6%
VGKVanguard FTSE Europe ETF0.9%
VYMIVanguard International High Dividend Yield ETF0.8%
EFAiShares MSCI EAFE ETF0.7%
VEAVanguard FTSE Developed Markets ETF0.5%
VEUVanguard FTSE All-World ex-US ETF0.4%
VXUSVanguard Total International Stock ETF0.3%
URTHiShares MSCI World ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%